Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accumulated Depreciation (2020 - 2023)

Relay Therapeutics (RLAY) has disclosed Accumulated Depreciation for 4 consecutive years, with $23.6 million as the latest value for Q4 2023.

  • Quarterly Accumulated Depreciation rose 28.24% to $23.6 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $23.6 million through Dec 2023, up 28.24% year-over-year, with the annual reading at $23.6 million for FY2023, 28.24% up from the prior year.
  • Accumulated Depreciation for Q4 2023 was $23.6 million at Relay Therapeutics, up from $18.4 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $23.6 million in Q4 2023, with the low at $10.5 million in Q4 2020.
  • Average Accumulated Depreciation over 4 years is $16.7 million, with a median of $16.4 million recorded in 2021.
  • The sharpest move saw Accumulated Depreciation skyrocketed 36.44% in 2021, then rose 27.99% in 2022.
  • Over 4 years, Accumulated Depreciation stood at $10.5 million in 2020, then surged by 36.44% to $14.4 million in 2021, then grew by 27.99% to $18.4 million in 2022, then rose by 28.24% to $23.6 million in 2023.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $23.6 million, $18.4 million, and $14.4 million for Q4 2023, Q4 2022, and Q4 2021 respectively.